中国银河资产增资泰州医药赋能产业升级

Group 1 - China Galaxy Asset is committed to integrating national strategic services with its core business, directing financial resources towards the pharmaceutical industry to support the "Strong Pharmaceutical Nation" mission and promote healthy development of the real economy [1] - China Galaxy Asset has implemented a market-oriented debt-to-equity swap to increase capital for Taizhou Pharmaceutical, facilitating the acceleration of high-quality industrial resource aggregation and enhancing its "R&D-incubation-industrialization" ecosystem [1] - Taizhou Pharmaceutical, a leading enterprise in Jiangsu Province, has been recognized as one of the top ten biopharmaceutical industrial parks in China, but faces pressure on its capital structure due to significant investment and long funding cycles in the construction of the pharmaceutical city [1] Group 2 - The debt-to-equity swap by China Galaxy Asset helps Taizhou Pharmaceutical reduce its asset-liability ratio and financial costs, fundamentally optimizing its capital structure and enhancing its operational capabilities and market competitiveness [2] - This initiative not only alleviates financial pressure on the enterprise but also strengthens its foundation for stable and healthy long-term development, serving as a model for local state-owned enterprises in their transformation [2] - The successful implementation of the debt-to-equity swap highlights China Galaxy Asset's role as a financial risk mitigator, social resource allocator, and service provider for the real economy, providing a reference model for financial services in the "Strong Pharmaceutical Nation" initiative [2]